MindMaze Therapeutics

(OTC) RLFTF

Current Price$0.48

Market Cap$75.55M

Since IPO (2025)-80%

5 Year-99%

1 Year-85%

1 Month+19%

MindMaze Therapeutics Financials at a Glance

Market Cap

$75.55M

Revenue (TTM)

CHF 12.65M

Net Income (TTM)

-CHF 63.28M

EPS (TTM)

-$1.56

P/E Ratio

-0.30

Dividend

$0.00

Beta (Volatility)

0.30 (Low)

Dividend

$0.00

Beta (Volatility)

0.30 (Low)

Price

$0.48

Volume

1,495

Open

$0.51

Price

$0.48

Volume

1,495

Open

$0.51

Previous Close

$0.47

Daily Range

$0.48 - $0.51

52-Week Range

$0.33 - $4.88

Dividend

$0.00

Beta (Volatility)

0.30 (Low)

Price

$0.48

Volume

1,495

Open

$0.51

Previous Close

$0.47

Daily Range

$0.48 - $0.51

52-Week Range

$0.33 - $4.88

RLFTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MindMaze Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Alexandre Capet

Website

www.mindmazetherapeutics.com

Headquarters

Lausanne, 1202, CH

RLFTF Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-41%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-3.33%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$75.55M

Shares Outstanding

159.10M

Volume

1.50K

Avg. Volume

3.75K

Financials (TTM)

Gross Profit

CHF 5.84M

Operating Income

-CHF 18.89M

EBITDA

-CHF 16.58M

Operating Cash Flow

-CHF 2.92M

Capital Expenditure

-CHF 172.00K

Free Cash Flow

-CHF 3.09M

Cash & ST Invst.

CHF 15.08M

Total Debt

CHF 2.14M

MindMaze Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2025YOY CHG

Revenue

CHF 1.22M

-59.7%

Gross Profit

CHF 619.00K

+110.8%

Gross Margin

50.82%

N/A

Market Cap

$75.55M

N/A

Market Cap/Employee

$2.44M

N/A

Employees

N/A

Net Income

-CHF 4.48M

+92.1%

EBITDA

-CHF 4.02M

+20.6%

Quarterly Fundamentals

Name

Q2 2025YOY CHG

Net Cash

CHF 10.60M

+11.0%

Accounts Receivable

CHF 1.47M

-29.0%

Inventory

CHF 923.00K

+105.1%

Long Term Debt

CHF 1.53M

-34.8%

Short Term Debt

CHF 369.00K

-58.6%

Return on Assets

N/A

Return on Invested Capital

N/A

Free Cash Flow

-CHF 3.77M

+65.2%

Operating Cash Flow

-CHF 3.76M

+64.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

INNMFAmplia Therapeutics Limited

INNMFAmplia Therapeutics Limited$0.10-3.92%

VEXTFVext Science, Inc.

VEXTFVext Science, Inc.$0.20+6.29%

CVALFCovalon Technologies Ltd.

CVALFCovalon Technologies Ltd.$1.58-3.07%

SEOVFSernova Corp.

SEOVFSernova Corp.$0.11+4.41%

OTLCOncotelic Therapeutics, Inc.

OTLCOncotelic Therapeutics, Inc.$0.06+3.40%

ACHFFArch Biopartners Inc.

ACHFFArch Biopartners Inc.$0.32+0.92%

HBPCFHelix BioPharma Corp.

HBPCFHelix BioPharma Corp.$1.71+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

CZRCaesars Entertainment

CZRCaesars Entertainment$29.10+0.01%

IUSBiShares Trust - iShares Core Universal Usd Bond ETF

IUSBiShares Trust - iShares Core Universal Usd Bond ETF$46.18+0.00%

RCATRed Cat

RCATRed Cat$14.34+0.34%

ATPCAgape Atp

ATPCAgape Atp$6.41+1.25%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$38.39-0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$16.43+0.01%

SIDUSidus Space

SIDUSidus Space$5.19-0.15%

Questions About RLFTF

What is the current price of MindMaze Therapeutics?

MindMaze Therapeutics is trading at $0.48 per share.

What is the 52-week range for MindMaze Therapeutics?

Over the past 52 weeks, MindMaze Therapeutics has traded between $0.33 and $4.88.

How much debt does MindMaze Therapeutics have?

As of the most recent reporting period, MindMaze Therapeutics reported total debt of CHF 2.36M.

How much cash does MindMaze Therapeutics have on hand?

MindMaze Therapeutics reported CHF 16.64M in cash and cash equivalents in its most recent financial results.

What is MindMaze Therapeutics’s dividend yield?

MindMaze Therapeutics does not currently have a dividend yield.

MindMaze Therapeutics

MindMaze Therapeutics Financials at a Glance

RLFTF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About MindMaze Therapeutics

RLFTF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

MindMaze Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About RLFTF

What is the current price of MindMaze Therapeutics?

What is the 52-week range for MindMaze Therapeutics?

How much debt does MindMaze Therapeutics have?

How much cash does MindMaze Therapeutics have on hand?

What is MindMaze Therapeutics’s dividend yield?

Premium Investing Services